Astellas Unveils Cancer Research Advances at ESMO 2024

Astellas Pharma Inc. presented significant advancements in cancer research during the 2024 European Society for Medical Oncology (ESMO) Congress held in Barcelona from September 13-17. The company showcased eight abstracts, including two oral presentations, highlighting new clinical data from its oncology portfolio and lead pipeline programs targeting various cancer types. Notable studies included the Phase 3 EV-302 trial, which evaluated the combination of enfortumab vedotin and pembrolizumab for treating locally advanced or metastatic urothelial cancer, demonstrating promising results across patient subgroups. Additionally, Astellas shared final overall survival data from the Phase 3 SPOTLIGHT and GLOW trials, focusing on zolbetuximab plus chemotherapy for HER2-negative gastric or GEJ adenocarcinoma. Updates from a Phase 2 trial assessing zolbetuximab in combination with gemcitabine and nab-paclitaxel for Claudin 18.2-positive metastatic pancreatic cancer were also presented, indicating potential benefits of enzalutamide in various age groups. The company introduced Phase 1 data for ASP3082, a novel protein degrader targeting KRAS G12D mutations, and preclinical data for ASP1570, a DGKζ inhibitor, both showing promise for advanced solid tumors. These findings underscore Astellas' commitment to advancing cancer treatment through innovative therapies and collaborations. The presentations at ESMO 2024 reflect Astellas' strategic focus on developing effective cancer therapies, aiming to improve patient outcomes and address unmet medical needs in oncology. The data presented not only highlights the strength of Astellas' portfolio but also emphasizes the transformative potential of its pipeline in the fight against cancer.